Trial Profile
Metformin, Exenatide, and Glargine Insulin in Combination for Treatment of Patients With Type 2 Diabetes.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Insulin glargine; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms MEXELIN
- 03 May 2012 Actual patient number added 40 according to ClinicalTrials.gov.
- 12 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Jul 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.